Interleukin-18, interferon-γ, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease

被引:52
作者
Setsuda, J
Teruya-Feldstein, J
Harris, NL
Ferry, JA
Sorbara, L
Gupta, G
Jaffe, ES
Tosato, G
机构
[1] NCI, Hematopathol Sect, Pathol Lab, NIH, Bethesda, MD 20892 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA USA
[3] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD USA
关键词
D O I
10.1016/S0002-9440(10)65119-X
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
T cell immunodeficiency plays an important role in the pathogenesis of posttransplant lymphoproliferative disease (PTLD) by permitting the unbridled expansion of Epstein-Barr virus (EBV)-infected B lymphocytes. However, factors other than T cell function may contribute to PTLD pathogenesis because PTLD infrequently develops even in the context of severe T cell immunodeficiency, and athymic mice that are T-cell-immunodeficient can reject EBV-immortalized cells. Here we report that PTLD tissues express significantly lower levels of IL-18, interferon-gamma (IFN-gamma), Mig, and RANTES compared to lymphoid tissues diagnosed with acute EBV-induced infectious mononucleosis, as assessed by semiquantitative RT-PCR analysis. Other cytokines and chemokines are expressed at similar levels. Immunohistochemistry confirmed that PTLD tissues contain less IL-18 and Mig protein than tissues with infectious mononucleosis. IL-18, primarily a monocyte product, promotes the secretion of IFN-gamma, which stimulates Mig and RANTES expression. Both IL-18 and Mig display antitumor activity in mice involving inhibition of angiogenesis, These results document greater expression of IL-18, IFN-gamma, Mig, and RANTES in lymphoid tissues with acute EBV-induced infectious mononucleosis compared to tissues with PTLD and raise the possibility that these mediators participate in critical host responses to EBV infection.
引用
收藏
页码:257 / 265
页数:9
相关论文
共 50 条
[1]
PHENOTYPE OF RECOVERING LYMPHOID-CELL POPULATIONS AFTER MARROW TRANSPLANTATION [J].
AULT, KA ;
ANTIN, JH ;
GINSBURG, D ;
ORKIN, SH ;
RAPPEPORT, JM ;
KEOHAN, ML ;
MARTIN, P ;
SMITH, BR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1985, 161 (06) :1483-1502
[2]
ACTIVATION OF DUAL T-CELL SIGNALING PATHWAYS BY THE CHEMOKINE RANTES [J].
BACON, KB ;
PREMACK, BA ;
GARDNER, P ;
SCHALL, TJ .
SCIENCE, 1995, 269 (5231) :1727-1730
[3]
Beatty PR, 1997, J IMMUNOL, V158, P4045
[4]
Interleukin-10 and Epstein-Barr virus-induced posttransplant lymphoproliferative disorder [J].
Birkeland, SA ;
Bendtzen, K .
TRANSPLANTATION, 1996, 61 (09) :1425-1426
[5]
CHAN SH, 1992, J IMMUNOL, V148, P92
[6]
MANAGEMENT OF LYMPHOPROLIFERATIVE DISORDERS AFTER CARDIAC TRANSPLANTATION [J].
CHEN, JM ;
BARR, ML ;
CHADBURN, A ;
FRIZZERA, G ;
SCHENKEL, FA ;
SCIACCA, RR ;
REISON, DS ;
ADDONIZIO, LJ ;
ROSE, EA ;
KNOWLES, DM ;
MICHLER, RE .
ANNALS OF THORACIC SURGERY, 1993, 56 (03) :527-538
[7]
POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER IN RENAL-ALLOGRAFT RECIPIENTS - CLINICAL-EXPERIENCE AND RISK FACTOR-ANALYSIS IN A SINGLE-CENTER [J].
COCKFIELD, SM ;
PREIKSAITIS, JK ;
JEWELL, LD ;
PARFREY, NA .
TRANSPLANTATION, 1993, 56 (01) :88-96
[8]
Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis [J].
Coughlin, CM ;
Salhany, KE ;
Wysocka, M ;
Aruga, E ;
Kurzawa, H ;
Chang, AE ;
Hunter, CA ;
Fox, JC ;
Trinchieri, G ;
Lee, WMF .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (06) :1441-1452
[9]
Mig and IP-10: CXC chemokines that target lymphocytes [J].
Farber, JM .
JOURNAL OF LEUKOCYTE BIOLOGY, 1997, 61 (03) :246-257
[10]
FERRY JA, 1989, MODERN PATHOL, V2, P583